HRP20180359T1 - Liječenje bolesti uporabom tolerogenskog farmaceutskog pripravka - Google Patents
Liječenje bolesti uporabom tolerogenskog farmaceutskog pripravka Download PDFInfo
- Publication number
- HRP20180359T1 HRP20180359T1 HRP20180359TT HRP20180359T HRP20180359T1 HR P20180359 T1 HRP20180359 T1 HR P20180359T1 HR P20180359T T HRP20180359T T HR P20180359TT HR P20180359 T HRP20180359 T HR P20180359T HR P20180359 T1 HRP20180359 T1 HR P20180359T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- use according
- cells
- preparation
- administration
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 14
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000003614 tolerogenic effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 7
- 230000001640 apoptogenic effect Effects 0.000 claims 4
- 210000001539 phagocyte Anatomy 0.000 claims 4
- 230000008105 immune reaction Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 238000003501 co-culture Methods 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000005251 gamma ray Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Farmaceutski pripravak, naznačen time, da se upotrebljava u prevenciji ili liječenju patološke imunološke reakcije, te time, da obuhvaća površinski isplivale fagocite s apoptotskim stanicama, koji se mogu dobiti iz njihove ko-kulture.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time, da se navedeni površinski isplivao materijal može dobiti putem postupka koji obuhvaća sljedeće korake:
a) pribavljanje fagocita,
b) pribavljanje apoptotskih stanica,
c) ispiranje stanica iz koraka a) i b),
d) ko-kultiviranje stanica iz koraka a) i b),
e) odvajanje površinski isplivanog materijala iz stanica.
3. Farmaceutski pripravak za uporabu prema zahtjevu 1 ili 2, naznačen time, da su apoptotske stanice dobivene putem induciranja apoptoze odabranog iz skupine koju čine hipoksija, ozon, zagrijavanje, radijacija, kemijska sredstva, osmotski tlak, pomak pH-vrijednosti, iradijacija X-zrakama, iradijacija gama-zrakama, UV-iradijacija, deprivacija seruma, kortikoidi ili njihove kombinacije.
4. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se ko-kultura održava u fiziološkoj otopini.
5. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da kod apoptotskih stanica radi o leukocitima.
6. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da su fagociti i/ili leukociti dobiveni iz perifernih krvnih mononuklearnih stanica (PBMC).
7. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da su fagociti makrofagne ili dendritičke stanice.
8. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 2 do 7, naznačen time, da se materijal koji je isplivao na površinu u koraku e), podvrgava iradijaciji u dodatnom koraku f).
9. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se navedeni pripravak prilagođava za intrakardijalnu primjenu, intraarterijsku primjenu, subkutanu primjenu, intramuskularnu primjenu, intraorgansku primjenu ili intravenoznu primjenu.
10. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da navedeni pripravak dodatno obuhvaća farmaceutski prihvatljivo pomoćno sredstvo.
11. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se navedeni pripravak liofilizira.
12. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 11, naznačen time, da se kod navedene patološke imunološke reakcije, radi o upalnoj imunološkoj reakciji, autoimunoj bolesti ili bolesti koja se odnosi na transplantaciju.
13. Farmaceutski pripravak za uporabu prema zahtjevu 12, naznačen time, da navedena autoimuna bolest je reumatoidni artritis [RA], upalna bolest crijeva [IBD].
14. Farmaceutski pripravak za uporabu prema zahtjevu 12, naznačen time, da se kod navedene bolesti koja se odnosi na transplantaciju, radi o bolesti: presadak protiv domaćina [GVHD].
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305009 | 2013-01-07 | ||
| EP14700238.0A EP2941257B1 (en) | 2013-01-07 | 2014-01-07 | Disease therapy using a tolerogenic pharmaceutical preparation |
| PCT/EP2014/050167 WO2014106666A1 (en) | 2013-01-07 | 2014-01-07 | Disease therapy using a tolerogenic pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180359T1 true HRP20180359T1 (hr) | 2018-05-04 |
Family
ID=47559360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180359TT HRP20180359T1 (hr) | 2013-01-07 | 2018-02-27 | Liječenje bolesti uporabom tolerogenskog farmaceutskog pripravka |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10653758B2 (hr) |
| EP (1) | EP2941257B1 (hr) |
| CY (1) | CY1119957T1 (hr) |
| DK (1) | DK2941257T3 (hr) |
| ES (1) | ES2657675T3 (hr) |
| HR (1) | HRP20180359T1 (hr) |
| HU (1) | HUE038211T2 (hr) |
| LT (1) | LT2941257T (hr) |
| NO (1) | NO2941257T3 (hr) |
| PL (1) | PL2941257T3 (hr) |
| PT (1) | PT2941257T (hr) |
| RS (1) | RS56906B1 (hr) |
| SI (1) | SI2941257T1 (hr) |
| WO (1) | WO2014106666A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL284985B2 (en) * | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20170138534A (ko) | 2015-04-21 | 2017-12-15 | 엔리벡스 테라퓨틱스 리미티드 | 치료적 혼주된 혈액 아폽토시스 세포 제제 및 이의 용도 |
| EP3416661A4 (en) * | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| FR3082730B1 (fr) * | 2018-06-21 | 2022-04-22 | Med Inn Pharma | Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
| WO2006120439A2 (en) * | 2005-05-10 | 2006-11-16 | Avaris Ab | Cellular vaccine and use thereof |
| CA2664567C (en) | 2006-10-04 | 2016-04-26 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
| EP2201954A1 (en) * | 2008-12-18 | 2010-06-30 | Aposcience AG | Pharmaceutical preparation |
-
2014
- 2014-01-07 ES ES14700238.0T patent/ES2657675T3/es active Active
- 2014-01-07 WO PCT/EP2014/050167 patent/WO2014106666A1/en active Application Filing
- 2014-01-07 SI SI201430584T patent/SI2941257T1/en unknown
- 2014-01-07 RS RS20180211A patent/RS56906B1/sr unknown
- 2014-01-07 PT PT147002380T patent/PT2941257T/pt unknown
- 2014-01-07 LT LTEP14700238.0T patent/LT2941257T/lt unknown
- 2014-01-07 PL PL14700238T patent/PL2941257T3/pl unknown
- 2014-01-07 DK DK14700238.0T patent/DK2941257T3/en active
- 2014-01-07 US US14/759,452 patent/US10653758B2/en active Active
- 2014-01-07 EP EP14700238.0A patent/EP2941257B1/en active Active
- 2014-01-07 HU HUE14700238A patent/HUE038211T2/hu unknown
- 2014-01-07 NO NO14700238A patent/NO2941257T3/no unknown
-
2018
- 2018-02-27 HR HRP20180359TT patent/HRP20180359T1/hr unknown
- 2018-02-27 CY CY20181100232T patent/CY1119957T1/el unknown
-
2020
- 2020-04-14 US US16/847,829 patent/US11793865B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2657675T3 (es) | 2018-03-06 |
| US11793865B2 (en) | 2023-10-24 |
| PT2941257T (pt) | 2018-03-06 |
| US20200237884A1 (en) | 2020-07-30 |
| NO2941257T3 (hr) | 2018-04-28 |
| US20150343039A1 (en) | 2015-12-03 |
| EP2941257A1 (en) | 2015-11-11 |
| EP2941257B1 (en) | 2017-11-29 |
| US10653758B2 (en) | 2020-05-19 |
| WO2014106666A1 (en) | 2014-07-10 |
| HUE038211T2 (hu) | 2018-10-29 |
| PL2941257T3 (pl) | 2018-05-30 |
| SI2941257T1 (en) | 2018-03-30 |
| DK2941257T3 (en) | 2018-02-26 |
| CY1119957T1 (el) | 2018-12-12 |
| RS56906B1 (sr) | 2018-05-31 |
| LT2941257T (lt) | 2018-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180359T1 (hr) | Liječenje bolesti uporabom tolerogenskog farmaceutskog pripravka | |
| HRP20191240T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| BR112017024777A2 (pt) | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? | |
| WO2013088148A3 (en) | Method of treatment employing therapeutic t cell product from mobilised donors | |
| MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
| BR112012020173A2 (pt) | anticorpos. | |
| JP2017522288A5 (hr) | ||
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| MX367473B (es) | Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos. | |
| Shiva et al. | The effect of inflammation on presence of cancer | |
| BR112016001775A2 (pt) | Composição, métodos de tratamento de um humano que foi diagnosticado com câncer, de prevenção de câncer em um humano com alto risco de ter câncer e de produção de uma composição, de uma população de células nk humanas antitumorais isoladas e de uma população de células dendríticas humanas antitumorais isoladas, células nk e dendríticas humanas isoladas, e, kit | |
| Vizel et al. | Multicenter retrospective analysis of the patients with sarcoidosis with a 10 year interval in observations | |
| Shin | Inverse relationship between soluble urokinase receptors and estimated glomerular filtration rate: a role for IL-2? | |
| Pencu et al. | Sarcoidosis-multiples skeletal bone involvement, skin, pleural and mediastinal manifestations | |
| Chinese Anti-Cancer Association et al. | A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China | |
| Romero | Microbiota intestinal their influence on chronic liver disease. Role in hepatocellular carcinoma | |
| Lakota | The Healing of Ulcus Cruris by Mesenchymal Stem Cells: No delay in wound healing by high-dose and standard chemotherapy | |
| Khaddaj AF et al. | Predictors of bleending recurrence in patients with non-varicose upper gastrointestinal bleeding | |
| Velibey | Thrombocytopenia: case report | |
| Mehdinejadiani et al. | Effect of Glycyrrhetinic Acid and Glycyrrhizic Acid on the Expression of CXCR4 in Epithelial Cells of Gastric Carcinoma | |
| Otsuka et al. | How does the physician interpret the patient's narrative as it relates to the physical exam?; New onset symptoms of cough and low grade fever in a patient with chronic cough | |
| Zhang et al. | Allicin, a major garlic constituent, ameliorates mesenteric lymph node dendritic cell-associated immunosuppression after trauma/hemorrhagic shock in rats | |
| Ibrahim | TRANSARTERIAL CHEMOEMBOLIZATION VERSUS BLAND EMBOLIZATION OF HEPATOCELLULAR CARCINOMA | |
| MX2015017557A (es) | Ciclodipéptidos de origen bacteriano con propiedades anticancerígenas y sus usos en el tratamiento del cáncer. | |
| Conley | Increase in blood pressure and diarrhoea in an elderly patient: case report |